Bank of New York Mellon’s Marker Therapeutics MRKR Stock Holding History

Bank of New York Mellon’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,576	Closed	-$4.19K	–	4424
2022 Q4	$4.19K	Hold	1,576	–	–	﹤0.01%	4452
2022 Q3	$6K	Hold	1,576	–	–	﹤0.01%	4528
2022 Q2	$5K	Hold	1,576	–	–	﹤0.01%	4574
2022 Q1	$7K	Hold	1,576	–	–	﹤0.01%	4649
2021 Q4	$15K	Hold	1,576	–	–	﹤0.01%	4601
2021 Q3	$27K	Hold	1,576	–	–	﹤0.01%	4491
2021 Q2	$44K	Sell	1,576 -6,218	-80%	-$164K	﹤0.01%	4338
2021 Q1	$174K	Sell	7,794 -1,694	-18%	-$38.8K	﹤0.01%	4090
2020 Q4	$137K	Sell	9,488 -211	-2%	-$3.28K	﹤0.01%	4041
2020 Q3	$145K	Hold	9,699	–	–	﹤0.01%	3913
2020 Q2	$201K	Buy	9,699 +1,432	+17%	+$31.3K	﹤0.01%	3796
2020 Q1	$157K	Hold	8,267	–	–	﹤0.01%	3798
2019 Q4	$238K	Sell	8,267 -51	-0.6%	-$1.85K	﹤0.01%	3871
2019 Q3	$424K	Buy	8,318 +134	+2%	+$7.92K	﹤0.01%	3629
2019 Q2	$648K	Buy	8,184 +5,746	+236%	+$341K	﹤0.01%	3478
2019 Q1	$161K	Sell	2,438 -249	-9%	-$14.5K	﹤0.01%	3926
2018 Q4	$149K	Buy	+2,687	New	+$196K	﹤0.01%	3903

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon's MRKR Position: Q1 2023 in Review

Bank of New York Mellon sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 1,576 shares — an estimated $4.19K sold.

Bank of New York Mellon first reported a position in MRKR in Q4 2018 and held it in 17 quarters. The position peaked at $648K in Q2 2019. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

Bank of New York Mellon reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
Bank of New York Mellon sold 1,576 Marker Therapeutics shares in Q1 2023, an estimated $4.19K.
Bank of New York Mellon first reported a position in Marker Therapeutics in Q4 2018 and held it in 17 quarters.
Bank of New York Mellon's Marker Therapeutics position peaked at $648K in Q2 2019.
30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Bank of New York Mellon's 13F filing for Q1 2023, filed 9 May 2023.